|Table of Contents|

The clinicopathological features of breast cancer patients with low HER-2 expression

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 14
Page:
2566-2569
Research Field:
Publishing date:

Info

Title:
The clinicopathological features of breast cancer patients with low HER-2 expression
Author(s):
YU Maowu; ZHOU Sujuan; CHEN Yun
Department of Pathology,Ningde Municipal Hospital of Ningde Normal University,Fujian Ningde 352100,China.
Keywords:
low HER-2 expression; breast cancer; clinical pathology; prognosis
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.14.012
Abstract:
Objective:To investigate the clinicopathological features of breast cancer patients with low HER-2 expression,and to provide clinicopathological data support for independent classification and precise treatment.Methods:The clinicopathologic data of patients diagnosed with non-specific invasive breast cancer were collected,and the HER-2-negative patients were divided into two groups for comparative study:No expression of HER-2［The immunohistochemical staining showed HER-2(0)］and low expression of HER-2［The immunohistochemical staining showed HER-2(1+) or HER-2(2+) and no amplification was detected by in situ hybridization(ISH-)］.Results:Lymph node metastasis rate in breast cancer patients with low HER-2 expression were higher than those without HER-2 expression(P＜0.05).Spearman rank correlation analysis showed that the HER-2 expression level was positively correlated with lymph node metastasis rate (rs=0.210，P＜0.05).Conclusion:Low expression of HER-2 has clinicopathologic characteristics different from no expression of HER-2,and it is expected to become a new molecular type independently.Further study on it is conducive to changing the treatment mode of breast cancer patients with low expression of HER-2 and providing more accurate treatment.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］XIA CF,DONG XS,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chin Med J (Engl),2022,135(5):584-590.
［3］SHUI RH,LIANG XZ,LI XM,et al.Hormone receptor and human epidermal growth factor receptor 2 detection in invasive breast carcinoma:a retrospective study of 12,467 patients from 19 Chinese representative clinical centers［J］.Clinical Breast Cancer,2020,20(1):e65-e74.
［4］黄香,蒋梦萍,包胜南,等.2021年CSCO《乳腺癌诊疗指南》更新要点解读［J］.中国肿瘤外科杂志,2021,13(3):209-215. HUANG X,JIANG MP,BAO SN,et al.Update and interpretation of the 2021 guidelines for the diagnosis and treatment of breast cancer by Chinese society of clinical oncology(CSCO)［J］.Chin J Surg Oncol,2021,2021,13(3):209-215.
［5］中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2021年版）［J］.中国癌症杂志,2021,31(10):954-1040. Breast Cancer Committee of Chinese anti-Cancer Association.Guideline and standard for the diagnosis and treatment of breast cancer by Chinese anti-cancer association(2021 edition)［J］.China Oncol,2021,31(10):954-1040.
［6］SCHETTINI F,CHIC N,BRASO-MARISTANY F,et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer［J］.NPJ Breast Cancer,2021,7(1):1-13.
［7］《乳腺癌HER2检测指南(2019版)》编写组.乳腺癌HER2检测指南(2019版)［J］.中华病理学杂志,2019,48(3):169-175. The writing group of the HER2 testing guidelines in breast cancer (2019 edition).Guidelines for HER2 testing in breast cancer (2019 edition)［J］.Chin J Pathol,2019,48(3):169-175.
［8］AMIN MB,GREENE FL,EDGE SB,et al.The eighth edition AJCC cancer staging manual:Continuing to build a bridge from a population-based to amore"personalized"approach to cancer staging［J］.CA Cancer J Clin,2017,67(2):93-99.
［9］ALLISON KH,HAMMOND MEH,DOWSETT M,et al.Estrogen and progesterone receptor testing in breast cancer:ASCO/CAP guideline update［J］.J Clin Oncol,2020,38(12):1346-1366.
［10］MARANTA AF,BRODER S,FRITZSCHE C,et al.Do you know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer［J］.Breast,2020,51:120-126.
［11］LIU Q,HUANG SJ,DESAUTELS D,et al.Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer［J］.Comput Struct Biotechnol J,2023,21:2940-2949.
［12］VIGANO L,LOCATELLI A,ULISSE A,et al.Modulation of the estrogen/erbB2 receptors Cross-talk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor-and ErbB2-positive breast cancer［J］.Clin Cancer Res,2022,28(10):2167-2179.
［13］GINGRAS I,GEBHART G,DE AZAMBUJA E,et al.HER2-positive breast cancer is lost in translation:time for patient-centered research［J］.Nat Rev Clin Oncol,2017,14(11):669-681.
［14］HWANG KT,KIM J,JUNG J,et al.Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer:a population-based study using SEER database［J］.Clin Cancer Res,2019,25(6):1970-1979.
［15］CAN NT,BENNETT J,FLANNERY CA,et al.ECOG-ACRIN E2197:Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis［J］.Journal of Clinical Oncology,2023,41(16):515.
［16］ANDRIKOPOULOU A,ZOGRAFOS E,LIONTOS M,et al.Trastuzumab deruxtecan (DS-8201a):The latest research and advances in breast cancer［J］.Clin Breast Cancer,2021,21(3):e212-e219.
［17］MODI S,JACOT W,YAMASHITA T,et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer［J］.N Engl J Med,2022,387(1):9-20.
［18］DENKERT C,SEITHER F,SCHNEEWEISS A,et al.Clinical and molecular characteristics of HER2-low-positive breast cancer:pooled analysis of individual patient data from four prospective,neoadjuvant clinical trials［J］.Lancet Oncol,2021,22:1151-1161.
［19］HONG J,TONG YW,HE JR,et al.Association between tumor molecular subtype,clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy:potential implications for de-escalation of axillary surgery［J］.Ther Adv Med Oncol,2021,13:1-14.

Memo

Memo:
宁德师范学院2023年上半年校级科研项目，附属医院科研项目专项（编号：2023ZX710）
Last Update: 1900-01-01